NEW YORK (GenomeWeb) – Expedeon said today it has signed a supply and license agreement with Cell Guidance Systems for use of its Lightning-Link Rapid Biotin technology.
Cell Guidance Systems will use the technology for the development of its TRIFic (Time Resolved Immunofluorescence Exosome Detection Assay) immunoassays, which are intended for applications including the measurement of exosomes in plasma.
Expedeon's Rapid Biotin kit allows researchers to biotinylate antibodies, proteins, peptides, and other biomolecules with an amine group. The biotinylated molecule can then be extracted from a sample using streptavidin pulldown.
"The Lightning-Link Rapid Biotin technology is used to generate stable biotin conjugates as components of [the TRIFic] platform," Laur-Alexandru Botos, senior research scientists at Cell Guidance Systems, said in a statement. "We have found Expedeon's cutting-edge technologies to be reliable and meet the high standards that our customers demand, and will be invaluable in ensuring the TRIFic detection assay kits enable researcher[s] to save time and costs.”
Financial and other terms of the agreement were not disclosed.